Epistem provides a variety of tumour xenograft models from melanoma, colon, breast, lung, prostate, pancreatic and ovarian cancer.
In addition, we can establish and provide novel xenograft models using both proprietary and commercially available cell lines in a range of immunocompromised or immunocompetent hosts.
Administering novel therapeutic agents is typically via traditional methods (oral, intravenous or intraperitoneal injection), or more specialised routes such as intratumoral injection and minipump delivery. Subcutaneous Xenograft Models can also be utilised to study the effects of combination therapies, including chemotherapy and radiotherapy (for example, evaluation of radiosensitisers).
As well as tumour volume, histological, immunohistochemical, FACS and biomarker analysis, including Epistem’s proprietary plucked hair biomarker platform readouts are available.
Primary Readout
- Tumour volume
Intra study readouts
- PK/PD
- T-cell quantification
Further Readouts
- Histology and immunohistochemistry
- Flow cytometry
- Gene expression analysis
- Tumour, hair/skin biomarker identification and validation
Further readouts are available on request.
